Sanofi (SNY)

49.53
0.36 0.72
NASDAQ : Health Technology
Prev Close 49.89
Open 49.58
Day Low/High 49.37 / 49.93
52 Wk Low/High 37.62 / 51.84
Volume 1.61M
Avg Volume 2.61M
Exchange NASDAQ
Shares Outstanding 2.51B
Market Cap 124.08B
EPS 1.30
P/E Ratio 26.61
Div & Yield 1.17 (2.39%)
Mylan Still Isn't Cheap

Mylan Still Isn't Cheap

The EpiPen controversy makes this stock a shot in the dark.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Clinton goes after the drug companies again -- for starters.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Bret Jensen Reporting for Duty

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg

Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg

The mobile-gaming market is expected to surpass console games this year, according to Deloitte.

Sanofi's Chart Shows Promise

Sanofi's Chart Shows Promise

Our first upside target is the $50 to $52 area and a close below $40 would extend the base.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Morning Movers: BCS, LYG, RBS, GOLD, AU, SNY

U.K. banks continue to get crushed in the wake of last week's Brexit vote as gold, a typical safe-haven investment, surged ahead.

BioMarin Pharmaceuticals Jumps on Takeover Talk

BioMarin Pharmaceuticals Jumps on Takeover Talk

Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

The uptick in the small- and mid-cap space bodes well for future capital appreciation.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

Cramer: Worst May Be Over for Embattled Pharma

The M&A activity is an incredible and a welcome sign.

M&A Could Ignite Next Leg Up for Biotech

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

A Good Morning So Far

The market is off to a good start, as the futures had portended earlier. Industrial and construction stocks seem to be doing particularly well. Rail-car maker Greenbrier Cos. (GBX) continues to show strength even after a recent earnings report that ...

Novice Trade: GlaxoSmithKline

Novice Trade: GlaxoSmithKline

Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.

MannKind Investors Should Have Seen the Writing on the Wall

MannKind Investors Should Have Seen the Writing on the Wall

Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.

2016 Could Be the Year of the Eurozone Stock Markets

The ECB's monetary stimulus is working, and more may be on the way.

2 Speculative Biotech Stocks for 2016

2 Speculative Biotech Stocks for 2016

Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.

U.S. Carmakers Benefit the Most From Jump in European Car Sales

And four other things you need to know now.

Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser

Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser

TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.

Closing Bell: Sanofi Falls on Weak Diabetes Sales; Crude Tops $46

Closing Bell: Sanofi Falls on Weak Diabetes Sales; Crude Tops $46

Stocks ended the day lower in a quieter session of trading compared to Wednesday's blowout rally.

Building a Sweet 16 Portfolio, Part 1

Selection of stocks is tailor made for investor, given market parameters.

Sanofi, Marks & Spencer Offer European Value Says S&P Capital IQ

Sanofi, Marks & Spencer Offer European Value Says S&P Capital IQ

The European economy is growing and the volatility from the Greek exit drama is keeping a lid on stock valuations.

Here Are 3 Charts Showing You Why Illumina Is a Marvel

Here Are 3 Charts Showing You Why Illumina Is a Marvel

It's almost impossible to get too excited about its success.

Obamacare Ruling Means the Debate Is Over

Obamacare Ruling Means the Debate Is Over

As health-care stocks rally, it's time for politicians to move on.

What's So Great About an Up Opening?

Don't rely on Europe; it's too out of sync with U.S.